Skip to content

Cannabis and Seniors

Cannabis and Seniors

As more and more research comes out regarding the medical benefits of cannabis, it’s important to keep up with new research as it becomes available.  Here at Arfinn Med, we constantly review new studies and look at our own deidentified efficacy data to try to find any additional insights we can relay to our registered users. With that in mind, we took a closer look at research coming out of the University of Illinois and the University of Iowa regarding the medicinal benefit of cannabis on Seniors.

The research found “strong positive association” between the frequency of cannabis use by Seniors and self-reported improvements in pain, health-care utilization, and overall health-related quality of life. The researchers revealed they had “identified a strong positive association between higher frequency of cannabis use and improvement to HRQL and HCU [health-care utilization] scores.”

With many clinics seeing an increase in the amount of Seniors turning to medical cannabis, we wanted to identify some additional trends through querying our database of deidentified data for patient demographics 60 and above.

Similar to what this report indicated, we found that Seniors self-reported an average 3.7 resolution of symptoms which translates on our scale to just below a ‘significant resolution’ of symptoms. In addition to the overall efficacy, we found that chronic pain was the most frequently sited qualifying condition with both THC dominant and balanced ratios of THC and CBD being the most frequently used cannabis profiles.  Lastly, in terms of mode of consumption, tinctures were the preferred route.

If you are interested in learning more about the efficacy of medical cannabis and would like to add our electronic medical record (EMR), practice management, and telehealth platform to your practice, please schedule a quick demo by contacting info@arfinnmed.com or by clicking here!

Stories you may be interested in

An Alternative Treatment for Parkinson’s Patients

April is Parkinson’s Awareness Month and an opportune time to highlight the disease and how medical marijuana may be a beneficial treatment option for those living with the condition. Many Parkinson’s patients find themselves desperate for alternative treatment options that provide sufficient relief of their symptoms and help avoid or postpone the need for surgery…
Read More

New Feature Updates

It’s a new feature alert! At Arfinn Med we always work to make sure we are the industry leading software platform and EMR for medical cannabis providers and clinics. Keeping with that sentiment, we’ve recently updated two features that have been very popular with Arfinn Med users.  Those are the customizable consent and confirmation page…
Read More

Thanks to the Farm Bill, Hemp Is Legal. Here’s What It Means for CBD.

On Tuesday, the Senate voted to approve a new an $867 billion farm bill, and on Wednesday, it passed in Congress. While the bill has plenty of positive merits, the one people are perhaps most excited about is the fact that it will legalize the production, sale, and distribution of industrial hemp at a federal…
Read More

Aching for a Better Alternative?

To close out Arthritis Awareness Month, we’re highlighting how medical marijuana may be a beneficial alternative treatment for this painful and debilitating disease. With over 31 million Americans suffering from various types of arthritis, the condition stands as the leading disability throughout the U.S. As many may know, arthritis is most common among the middle-aged…
Read More

Cannabis and autism, explained

Over the past decade, autistic people and their families have increasingly experimented with medical marijuana and products derived from it. Many hope these compounds will alleviate a range of autism-related traits and problems. But scientists are still in the early stages of rigorous research into marijuana’s safety and effectiveness, which means that people who pursue…
Read More

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More

Leave a Comment

You must be logged in to post a comment.